Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) have been given a consensus recommendation of “Hold” by the seven research firms that are presently covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $4.94.

CARM has been the topic of several analyst reports. Baird R W cut shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. D. Boral Capital reaffirmed a “buy” rating and issued a $12.00 target price on shares of Carisma Therapeutics in a report on Monday, January 13th. BTIG Research downgraded Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 10th. Robert W. Baird cut Carisma Therapeutics from an “outperform” rating to a “neutral” rating and cut their price objective for the stock from $10.00 to $1.00 in a research report on Thursday, December 12th. Finally, Evercore ISI reaffirmed an “in-line” rating and set a $0.70 target price (down from $4.00) on shares of Carisma Therapeutics in a research report on Wednesday, December 11th.

Carisma Therapeutics Price Performance

Carisma Therapeutics stock opened at $0.50 on Friday. The company has a debt-to-equity ratio of 1.39, a quick ratio of 3.23 and a current ratio of 3.23. The stock has a market capitalization of $20.83 million, a price-to-earnings ratio of -0.32 and a beta of 1.56. The stock’s 50 day moving average price is $0.55 and its two-hundred day moving average price is $0.86. Carisma Therapeutics has a 52-week low of $0.38 and a 52-week high of $2.77.

Carisma Therapeutics (NASDAQ:CARM) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, meeting analysts’ consensus estimates of ($0.31). The firm had revenue of $3.39 million during the quarter. Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%. On average, equities analysts predict that Carisma Therapeutics will post -1.32 earnings per share for the current year.

Institutional Trading of Carisma Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Wexford Capital LP boosted its position in shares of Carisma Therapeutics by 75.5% in the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after acquiring an additional 15,000 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Carisma Therapeutics in the 2nd quarter worth approximately $40,000. Finally, Barclays PLC boosted its holdings in Carisma Therapeutics by 3,661,933.3% in the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after purchasing an additional 549,290 shares during the period. Institutional investors own 44.27% of the company’s stock.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.